Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial - Finn, R S; Ryoo, B Y; Merle, P; KEYNOTE-240 Investigators (J Clin Oncol, 2020)